Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors.

Grajo JR, Terry RS, Ruoss J, Noennig BJ, Pavlinec JG, Bozorgmehri S, Crispen PL, Su LM.

Urology. 2019 Mar;125:123-130. doi: 10.1016/j.urology.2018.11.036. Epub 2018 Dec 12.

PMID:
30552939
2.

Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract.

Noennig B, Bozorgmehri S, Terry R, Otto B, Su LM, Crispen PL.

Bladder Cancer. 2018 Oct 29;4(4):389-394. doi: 10.3233/BLC-180174.

3.

Delayed Intervention of Small Renal Masses on Active Surveillance.

Gupta M, Blute ML Jr, Su LM, Crispen PL.

J Kidney Cancer VHL. 2017 May 24;4(2):24-30. doi: 10.15586/jkcvhl.2017.75. eCollection 2017.

4.

Lymph Node Dissection for Small Renal Masses.

Blute ML Jr, Gupta M, Crispen PL.

Urol Clin North Am. 2017 May;44(2):269-274. doi: 10.1016/j.ucl.2016.12.012. Epub 2017 Mar 14. Review.

PMID:
28411918
5.

How Best to Predict Tumor Control and Renal Function after Treatment of Renal Masses.

Crispen PL.

J Urol. 2015 Oct;194(4):867-8. doi: 10.1016/j.juro.2015.07.077. Epub 2015 Jul 14. No abstract available.

PMID:
26184068
6.

Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.

Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB.

Clin Cancer Res. 2015 Sep 15;21(18):4224-33. doi: 10.1158/1078-0432.CCR-15-0260. Epub 2015 May 21.

7.

New primary malignancy masquerading as metastatic prostate adenocarcinoma.

Szwed EA, Sliesoraitis S, Nguyen TC, Nguyen MN, Moreb JS, Zlotecki RA, Crispen PL, Dang NH, Dang LH.

Case Rep Oncol Med. 2015;2015:358572. doi: 10.1155/2015/358572. Epub 2015 Feb 19.

8.

Displacement of the Spleen Mimicking Renal Cell Cancer Recurrence Post-Nephrectomy: A Case Report.

Emanuels CS, Timmerman KD, Aijaz T, Nguyen TC, Jest N, Drane WE, Gilbert SM, Crispen PL, Su LM, Deitte LA, Dang LH.

J Kidney Cancer VHL. 2015 Jun 20;2(3):130-133. doi: 10.15586/jkcvhl.2015.36. eCollection 2015.

9.

Metabolic bone disease following urinary diversion in adults.

Vyas P, Crispen PL.

Curr Opin Urol. 2014 Nov;24(6):614-8. doi: 10.1097/MOU.0000000000000114. Review.

PMID:
25203244
10.

Patterns of care for renal surgery: Underutilization of nephron-sparing procedures.

Hammett J, Ko J, Byrd N, Crispen PL, Krupski TL.

Can Urol Assoc J. 2013 May-Jun;7(5-6):E386-92. doi: 10.5489/cuaj.12066. Epub 2013 Jun 12.

11.

Small renal masses: the effect of illness uncertainty during active surveillance.

Crispen PL.

Nat Rev Urol. 2013 May;10(5):255-6. doi: 10.1038/nrurol.2013.63. Epub 2013 Apr 2. No abstract available.

PMID:
23545815
12.

Editorial comment.

Crispen PL.

Urology. 2013 May;81(5):997; discussion 997. doi: 10.1016/j.urology.2012.10.081. Epub 2013 Feb 28. No abstract available.

PMID:
23453655
13.

Association of tumor size, location, R.E.N.A.L., PADUA and centrality index score with perioperative outcomes and postoperative renal function.

Bylund JR, Gayheart D, Fleming T, Venkatesh R, Preston DM, Strup SE, Crispen PL.

J Urol. 2012 Nov;188(5):1684-9. doi: 10.1016/j.juro.2012.07.043. Epub 2012 Sep 19.

PMID:
22998902
14.

Association of clinical and radiographic features with perinephric "sticky" fat.

Bylund JR, Qiong H, Crispen PL, Venkatesh R, Strup SE.

J Endourol. 2013 Mar;27(3):370-3. doi: 10.1089/end.2012.0205. Epub 2012 Nov 27.

15.

Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.

Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, Lohse CM, Leibovich BC.

Cancer. 2012 Sep 15;118(18):4412-20. doi: 10.1002/cncr.26695. Epub 2012 Jan 3.

16.

Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma.

Crispen PL, Soljic A, Stewart G, Kutikov A, Davenport D, Uzzo RG.

J Urol. 2012 Oct;188(4):1089-93. doi: 10.1016/j.juro.2012.06.019. Epub 2012 Aug 15.

17.

NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.

Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM.

Can J Urol. 2012 Aug;19(4):6345-50.

PMID:
22892257
18.

Bilateral ovarian steroid cell tumours and massive macronodular adrenocortical disease in a patient with hereditary leiomyomatosis and renal cell cancer syndrome.

Arora R, Eble JN, Pierce HH, Crispen PL, DeSimone CP, Lee EY, Karabakhtsian RG.

Pathology. 2012 Jun;44(4):360-3. doi: 10.1097/PAT.0b013e328353bf5a. No abstract available.

PMID:
22565324
19.

Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons.

Weight CJ, Crispen PL, Breau RH, Kim SP, Lohse CM, Boorjian SA, Thompson RH, Leibovich BC.

BJU Int. 2013 May;111(5):731-8. doi: 10.1111/j.1464-410X.2012.11112.x. Epub 2012 Apr 13.

20.

Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Crispen PL, Blute ML.

Curr Urol Rep. 2012 Feb;13(1):38-46. doi: 10.1007/s11934-011-0225-x. Review.

PMID:
22105577
21.

Hand-assisted laparoscopic partial nephrectomy without formal collecting system closure: perioperative outcomes in 104 consecutive patients.

Bylund JR, Clark CJ, Crispen PL, Lagrange CA, Strup SE.

J Endourol. 2011 Dec;25(12):1853-7. doi: 10.1089/end.2011.0175. Epub 2011 Aug 24.

PMID:
21864024
22.

Treatment of patients with small renal masses: a survey of the American Urological Association.

Breau RH, Crispen PL, Jenkins SM, Blute ML, Leibovich BC.

J Urol. 2011 Feb;185(2):407-13. doi: 10.1016/j.juro.2010.09.092. Epub 2010 Dec 17.

PMID:
21168170
23.

Temporal relationship between positive margin rate after laparoscopic radical prostatectomy and surgical training.

Page JB, Davenport DL, Unnikrishnan R, Crispen PL, Venkatesh R, Strup SE.

Urology. 2011 Mar;77(3):626-30. doi: 10.1016/j.urology.2010.06.073. Epub 2010 Dec 13.

PMID:
21146859
24.

Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.

Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML.

Eur Urol. 2011 Jan;59(1):18-23. doi: 10.1016/j.eururo.2010.08.042. Epub 2010 Sep 15.

PMID:
20933322
25.

Penile intraepithelial neoplasia and other premalignant lesions of the penis.

Crispen PL, Mydlo JH.

Urol Clin North Am. 2010 Aug;37(3):335-42. doi: 10.1016/j.ucl.2010.04.003. Epub 2010 Jun 11. Review.

PMID:
20674690
26.

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?

Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML.

BJU Int. 2011 Mar;107(5):724-728. doi: 10.1111/j.1464-410X.2010.09488.x.

27.

Tissue microarrays: one size does not fit all.

Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED.

Diagn Pathol. 2010 Jul 7;5:48. doi: 10.1186/1746-1596-5-48.

28.

Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma.

Umbreit EC, Crispen PL, Shimko MS, Farmer SA, Blute ML, Frank I.

Cancer. 2010 Jul 15;116(14):3399-407. doi: 10.1002/cncr.25202.

29.

Unclassified renal cell carcinoma: impact on survival following nephrectomy.

Crispen PL, Tabidian MR, Allmer C, Lohse CM, Breau RH, Blute ML, Cheville JC, Leibovich BC.

Urology. 2010 Sep;76(3):580-6. doi: 10.1016/j.urology.2009.12.037. Epub 2010 Mar 12.

PMID:
20223503
30.

Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.

Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC.

J Urol. 2010 Apr;183(4):1309-15. doi: 10.1016/j.juro.2009.12.035. Epub 2010 Feb 19.

PMID:
20171681
31.

Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life.

Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML.

J Am Coll Surg. 2010 Feb;210(2):232-9. doi: 10.1016/j.jamcollsurg.2009.09.041. Epub 2009 Dec 3.

PMID:
20113945
32.

The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.

Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML.

J Urol. 2010 Mar;183(3):1003-9. doi: 10.1016/j.juro.2009.11.039. Epub 2010 Jan 21.

PMID:
20092854
33.

Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy.

Breau RH, Crispen PL, Jimenez RE, Lohse CM, Blute ML, Leibovich BC.

J Urol. 2010 Mar;183(3):903-8. doi: 10.1016/j.juro.2009.11.037. Epub 2010 Jan 18.

PMID:
20083271
34.

Editorial comment.

Crispen PL, Blute ML.

Urology. 2009 Nov;74(5):1046; author reply 1046-7. doi: 10.1016/j.urology.2009.05.081. No abstract available.

PMID:
19883819
35.

Radiation therapy after radical prostatectomy: impact on metastasis and survival.

Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML.

J Urol. 2009 Dec;182(6):2708-14. doi: 10.1016/j.juro.2009.08.027.

PMID:
19836762
36.

Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization.

Crispen PL, Blute ML.

Eur Urol. 2009 May;55(5):1161-2. No abstract available.

PMID:
19645090
37.

T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.

Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED.

Urology. 2009 Dec;74(6):1359-64. doi: 10.1016/j.urology.2009.03.007. Epub 2009 Jun 7.

38.

Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG.

Cancer. 2009 Jul 1;115(13):2844-52. doi: 10.1002/cncr.24338.

39.

Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.

Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ.

Clin Cancer Res. 2009 Mar 15;15(6):2174-80. doi: 10.1158/1078-0432.CCR-08-2262. Epub 2009 Mar 10.

40.

The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.

Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML.

J Urol. 2009 Jan;181(1):95-104; discussion 104. doi: 10.1016/j.juro.2008.09.016. Epub 2008 Nov 13.

PMID:
19012937
41.

Functional and oncological outcomes after orthotopic neobladder reconstruction in women.

Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML.

BJU Int. 2008 Dec;102(11):1551-5. doi: 10.1111/j.1464-410X.2008.07909.x. Epub 2008 Oct 8.

42.

Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies?

Crispen PL, Blute ML.

Eur Urol. 2009 Feb;55(2):307-9. doi: 10.1016/j.eururo.2008.09.054. Epub 2008 Oct 5. No abstract available.

PMID:
18838207
43.

Outcomes following partial nephrectomy by tumor size.

Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC.

J Urol. 2008 Nov;180(5):1912-7. doi: 10.1016/j.juro.2008.07.047. Epub 2008 Sep 17.

PMID:
18801543
44.

Predicting growth of solid renal masses under active surveillance.

Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG.

Urol Oncol. 2008 Sep-Oct;26(5):555-9. doi: 10.1016/j.urolonc.2008.03.010.

45.

Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.

Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED.

Clin Cancer Res. 2008 Aug 15;14(16):5150-7. doi: 10.1158/1078-0432.CCR-08-0536. Epub 2008 Aug 11.

46.

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.

Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I.

Clin Cancer Res. 2008 Aug 1;14(15):4800-8. doi: 10.1158/1078-0432.CCR-08-0731.

47.

Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm.

Crispen PL, Lohse CM, Blute ML.

Adv Urol. 2008:518091. doi: 10.1155/2008/518091.

48.

Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis.

Makhov P, Golovine K, Uzzo RG, Rothman J, Crispen PL, Shaw T, Scoll BJ, Kolenko VM.

Cell Death Differ. 2008 Nov;15(11):1745-51. doi: 10.1038/cdd.2008.106. Epub 2008 Jul 11.

49.

Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway.

Golovine K, Uzzo RG, Makhov P, Crispen PL, Kunkle D, Kolenko VM.

Prostate. 2008 Sep 15;68(13):1443-9. doi: 10.1002/pros.20810.

50.

Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy.

Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, Gettman MT.

J Endourol. 2008 Jul;22(7):1471-6. doi: 10.1089/end.2008.0056.

PMID:
18613784

Supplemental Content

Loading ...
Support Center